Is this neuroprotective drug good for my glaucoma patients? Some key factors in clinical decision-making.
Neuroprotection protects neurons from death after a primary insult, independent of that insult. Important clinical considerations include minimal interference with physiological processes, possible simultaneous or sequential treatment strategies, and most effective method of drug delivery. Clinicians' assessment of the neuroprotective value of any agent hinges on demonstration of efficacy by prospective randomized controlled trials. Use of a neuroprotectant will depend on the glaucomatous threat to a patient's visual function, as well as the agent's therapeutic index and its cost.
Goldberg
Ivan
I
Eye Associates, Glaucoma Services, Sydney Eye Hospital, University of Sydney, Australia. eyegoldberg@gmail.com
D003657:Decision Making; D016527:Drug Costs; D005901:Glaucoma / Q000188:drug therapy* / Q000191:economics; D006801:Humans; D018696:Neuroprotective Agents / Q000191:economics / Q000627:therapeutic use*; D009901:Optic Nerve Diseases / Q000188:drug therapy* / Q000191:economics; D017410:Practice Guidelines as Topic
D018696:Neuroprotective Agents